公开(公告)号：US20170100367A1

公开(公告)日：2017-04-13

申请号：US15314160

申请日：2015-05-27

Applicant: Bruce A. Littlefield ,  Eisai R&D Management Co., Ltd.

Inventor： Makoto ASANO ,  Bruce A. LITTLEFIELD ,  Junji MATSUI ,  Martin OLIVO ,  Yoichi OZAWA ,  Yanke YU

IPC: A61K31/357 ,  A61K31/7068 ,  A61K31/282 ,  A61K31/704 ,  A61K31/427 ,  A61K9/00 ,  A61K31/337

Abstract: The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.

公开(公告)号：US20180071247A1

公开(公告)日：2018-03-15

申请号：US15554540

申请日：2016-03-03

Applicant: MERCK SHARP & DOHME CORP. ,  Eisai R&D Management Co., Ltd.

Inventor： Junji MATSUI ,  Gursel AKTAN ,  Vassiliki KARANTZA ,  RuiRong YUAN ,  Yasuhiro FUNAHASHI ,  Erhan BERRAK

IPC: A61K31/357 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  A61K9/00

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.